WAVEMAN · COMPANY

MLAB · Mesa Laboratories Inc /Co/

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

MLAB

Name: MESA LABORATORIES INC /CO/ (MLAB) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

MESA LABORATORIES INC /CO/

MEDICAL DEVICES · INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL · CIK 0000724004

CLUSTER · 4 INSIDERSC-SUITE BUYING · 1FORM 144 · 4☆ WATCH

INSIDER NET · 180D

-$215.7K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+3.4%

XBRL, annual

NET MARGIN

2.7%

CONVERSIONS · 180D

codes C/M, not in net · $1.3M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$215.7K over 180 days

-$667.8K over 90 days

more than 53% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

fewer than five institutions report holding it

REVENUE

+3.4% year over year

below 64% of Medical Devices

MARGIN

2.7% net margin

more than 65% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

5.8% of shares outstanding short · 2.5 days to cover · settled 2026-07-31

more than 69% of Medical Devices

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$215.7K across 4 people in 180 days.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +101.2%

+101.2%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

4 insiders reported buying shares.

The record shows a net $215.7K sold by insiders over 180 days, $5.5M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, MESA LABORATORIES INC /CO/ insiders sold a net $215.7K of stock across 73 Form 4 purchases and sales, with 4 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Tripeny R Tony

Director

BUY

2026-08-13

900.0

$102.3K

Kadia Siddhartha

President and CEO

BUY

2026-08-13

7,093.0

$800.1K

Sullivan John James

Director

SELL

2026-08-13

7,093.0

$800.1K

Crennen Lyndsey Elizabeth

CAO

SELL

2026-06-22

442.0

$39.6K

Archbold Brian David

SVP Operations

SELL

2026-06-22

2,516.0

$225.2K

73 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 68 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Owens Gary M

FILED 2026-08-27

$2.6M

Owens Gary M

FILED 2026-08-21

$2.5M

Archbold Brian David

FILED 2026-06-22

$225.2K

Sakys John

FILED 2026-06-22

$253.0K

Executive pay vs shareholder return · Gary Owens

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$6.6M

$516.2K

$2.3M

-63%

-65%

2024

$6.6M

$7.9M

$2.3M

-50%

-67%

2023

$5.4M

$78.0K

$1.8M

-54%

-57%

2022

$5.2M

-$3.6M

$1.5M

-28%

-54%

2021

$18.1M

$16.8M

$1.5M

+5%

-34%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2026-03	2025-03	2024-03	2023-03
REVENUE	$249.1M	$241.0M	$216.2M	$219.1M
GROSS PROFIT	$158.3M	$150.9M	$133.2M	$133.7M
OPERATING INCOME	$18.5M	$16.3M	$-272.1M	$3.3M
NET INCOME	$6.7M	$-2.0M	$-254.2M	$930.0K
EPS (DILUTED)	1.21	-0.36	-47.20	0.17
OPERATING CASH FLOW	$42.8M	$46.8M	$44.1M	$28.0M
CASH	$26.9M	$27.3M	$28.2M	$32.9M
LONG-TERM DEBT	$67.5M	$71.2M	—	—
DIVIDENDS PAID	$3.5M	$3.5M	$3.4M	$3.4M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE